BIOSIMILAR PATH AT RISK
India high court bans promotion of Roche’s Herceptin biosimilars by Biocon, Mylan
By Cornelia Zou
Wednesday, February 12, 2014
HONG KONG – The High Court of Delhi has forbidden Biocon Ltd. and Mylan Inc. from comparing Canmab and Hertraz to Roche AG’s breast cancer drug Herceptin (trastuzumab), even though they were approved as biosimilar versions of the drug.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.